Related Experiment Video
Updated: Jun 5, 2026

High Content Screening Analysis to Evaluate the Toxicological Effects of Harmful and Potentially Harmful Constituents (HPHC)
Published on: May 10, 2016
Estimating area under the curve and relative exposure in a pharmacokinetic study with data below quantification limit
Liang Fang1, Peng Chen, Chunlei Ke
1Genentech, Inc., South San Francisco, California 94080, USA. fang.liang@gene.com
Abstract:
Area under the drug-concentration-over-time curve (AUC) is an important endpoint for many phase I/II clinical trials and laboratory assays. Drug concentrations are measured using laboratory assays with a lower limit of quantification (LLOQ). How to calculate AUC when some drug concentration data are below the LLOQ remains as a challenge. In this article, we develop a maximum likelihood method to estimate AUC and relative exposure (i.e., ratio of two AUCs) when data below LLOQ exists. We also compare the proposed method to several commonly used methods, including imputation with model-predicted values or ad hoc values (i.e., LLOQ, LLOQ/2, or zero) through a simulation study. The proposed method gives unbiased inference. Commonly used methods can provide biased estimation, especially when a large proportion of data is below LLOQ. Application to a case study is also presented.
Related Concept Videos
Measurement of Bioavailability: Pharmacokinetic Methods
Model-Independent Approaches for Pharmacokinetic Data: Noncompartmental Analysis
One important characteristic of noncompartmental analyses is that drug exposure increases proportionally with increasing doses. This relationship...
Dosage Regimens: Partial Pharmacokinetic Parameters
Noncompartmental Analysis: Miscellaneous Pharmacokinetic Parameters
One key aspect of the noncompartmental approach is determining a drug's total clearance. This can be done by dividing the drug dose by the area under the concentration-time curve from zero to infinity. The area under the concentration-time curve represents the drug's overall...
One-Compartment Open Model: Wagner-Nelson and Loo Riegelman Method for ka Estimation
On...
Bioavailability Study Design: Absolute Versus Relative Bioavailability

